Comment
doi: 10.1016/S2352-3026(22)00070-9.
Melflufen in multiple myeloma: the conclusion matters
Affiliations
- PMID: 35358437
- DOI: 10.1016/S2352-3026(22)00070-9
Item in Clipboard
Comment
Melflufen in multiple myeloma: the conclusion matters
Lancet Haematol.
2022 Apr.
No abstract available
Conflict of interest statement
I report receiving consulting fees from NOVA Research Company.
Comment in
-
Melflufen in multiple myeloma: the conclusion matters - Authors' reply.Lancet Haematol. 2022 Apr;9(4):e244-e245. doi: 10.1016/S2352-3026(22)00071-0. Lancet Haematol. 2022. PMID: 35358436 No abstract available.
Comment on
-
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.Lancet Haematol. 2022 Feb;9(2):e98-e110. doi: 10.1016/S2352-3026(21)00381-1. Epub 2022 Jan 12. Lancet Haematol. 2022. PMID: 35032434 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
